Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTABLETGeneric

ABACAVIR, DOLUTEGRAVIR AND LAMIVUDINE

ABACAVIR, DOLUTEGRAVIR, LAMIVUDINE

Standard Dose
30MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview ABACAVIR, DOLUTEGRAVIR AND LAMIVUDINE is listed in Drugs@FDA under application 217830 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient ABACAVIR, DOLUTEGRAVIR, LAMIVUDINE Form and strength TABLET - 30MG Sponsor MACLEODS PHARMACEUTICALS LTD Submission history Latest submission status date: 2025-09-17 00:00:00.

Structured Monograph

Clinical summary

Approval overview ABACAVIR, DOLUTEGRAVIR AND LAMIVUDINE is listed in Drugs@FDA under application 217830 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient ABACAVIR, DOLUTEGRAVIR, LAMIVUDINE Form and strength TABLET - 30MG Sponsor MACLEODS PHARMACEUTICALS LTD Submission history Latest submission status date: 2025-09-17 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.